Matrix metalloproteinases-2, -3, and -9 secreted by explants of benign and malignant lesions of the uterine cervix

International Journal of Gynecological Cancer

Volumn 14, Issue 2, 2004, Pages 333-340

  Arguello Ramirez J ^a   Perez Cardenas E ^a   Delgado Chavez R ^a   Solorza Luna, G ^a   Villa Trevino S ^a   Arenas Huertero, Francisco ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

Cervical carcinoma; Invasion; Metastasis; MMPs; Proteinases

Indexed keywords

GELATINASE A; GELATINASE B; STROMELYSIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOGENESIS; CLINICAL ARTICLE; DENSITOMETRY; ENZYME RELEASE; EXPLANT; EXTRACELLULAR MATRIX; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; ZYMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS;

EID: 2042526885     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891x.2004.014218.x     Document Type: Article

References (54)

1. Liotta L, Rao C, Barsky S. Tumor invasion and the extracellular matrix. Lab Invest 1983;49:636-49.
2. Liotta L. Tumor invasion and metastasis: role of the basement membrane. Am J Pathol 1984;117:339-48.
3. Liotta L. Tumor invasion and metastases-role of the extracellular matrix: rhoads memorial award lecture. Cancer Res 1986;46:1-7.
4. Matrisian L. The matrix-degrading metalloproteinases. Bioessays 1992;14:455-63.
5. Rodgers W. Matrix metalloproteinases and carcinogenesis. Hum Pathol 1999;30:363-4.
6. McCawley L, Matrisian L. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000;6:149-56.
7. Matrisian L. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
8. Ray J, Stetler-Stevenson W. The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062-72.
9. Miyagi E, Yasumitsu H, Hirahara F et al. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells. Jpn J Cancer Res 1995;86:568-76.
10. Powel W, Matrisian L. Complex roles of matrix metalloproteinases in tumor progression. In: Günthert U, Birchmeier W, eds. Attempts to Understand Metastasis Formation I. Metastasis-related molecules. New York, NY: Springer 1996: 1-21.
11. Silletti S, Raz A. Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis. In: Günthert, U, Birchmeier, W, eds. Attempts to Understand Metastasis Formation I. Metastasis-related molecules. New York, NY: Springer 1996: 22-9.
12. Murphy GJ, Murphy G, Reynolds J. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett 1991;289:4-7.
13. Uría J, López-Otín C. Matrix metalloproteinases as emergin targets for cancer therapy. Rev Oncología 2000;2:282-93.
14. Nelson AR, Fingleton B, Rothenbers ML, Matrsian L. Matrix metalloproteinases: biologic and clinical implications. J Clin Oncol 2000;18:1135-49.
15. Sutinen M, Kainulainen T, Hurskainen T et al. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer 1998;77:2239-45.
16. Arenas-Huertero F, Herrera-Goepfert R, Delgado-Chávez et al. Matrix metalloproteinases expressed in squamous cell carcinoma of the oral cavity: correlation with clinicopathologic features and neo-adjuvant chemotherapy response. J Exp Clin Cancer Res 1999;18:279-84.
17. Nawrocki B, Polette M, Marchand V et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantitative and morphological analyses. Int J Cancer 1997;72:556-64.
18. Sugiura Y, Shimada H, Seeger R, Laug W, DeClerck Y. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 1998;58:2209-16.
19. Lokeshwar B, Selzer M, Block N, Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 1993;53:4493-8.
20. Théret N, Musso O, Campion J et al. Overexpression of matrixmetalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Int J Cancer 1997;74:426-32.
21. Hähnel E, Dawkins H, Robbins P, Hähnel R. Expression of stromelysin-3 and nm23 in breast carcinoma and related tissues. Int J Cancer 1994;58:157-60.
22. Remacle A, Noël A, Duggan C et al. Assay of matrix metalloproteinases types 1,2,3 and 9 in breast cancer. Br J Cancer 1998;77:926-31.
23. Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A, Davaris P. Matrix metalloproteinase-1 and 3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 1999;30:436-42.
24. Tamakoshi K, Kikkawa F, Nawa A et al. Different pattern of zymography between human gynecologic normal and malignant tissues. Am J Obstet Gynecol 1994;171:478-84.
25. Ueno H, Yamashita K, Azumano I, Inoue M, Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 1999;84:470-7.
26. Marbaix E, Donnez J, Courtoy PJ, Eckhout Y. Progesterone regulates the activity of collagenase and related gelatinases A and B in human endometrial explants. Proc Natl Acad Sci USA 1992;89:11789-93.
27. Mohar-Betancourt A, Frias-Mendivil M, Beltrán-Ortega A. Epidemiología descriptiva del cáncer cervicouterino. Instituto Nacional de Cancerología 1985-1991. Rev Inst Nal Cancerol (Mex) 1993;39:1849-55.
28. Escandón-Romero C, Benítez-Martinez MG, Navarrete-Espinoza J, Vázquez-Martínez JL, Martinez-Montañez OG, Escobedo-De la Peña J. Epidemiología del cáncer cervicouterino en el Instituto Mexicano del Seguro Social. Salud Publica Mex 1992;34:607-12.
29. Muñoz N, Bosch FX, de Sanjosé S et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743-9.
30. Leibel SA, Fucks Z. Is local failure a cause of or a maker for metastatic dissemination in a carcinoma of the uterine cervix?. Int J Radiat Oncol Biol Phys 1992;24:77-81.
31. Fagundes H, Pérez C, Grigsby P, Lockett M. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1992;24:197-201.
32. Nuovo G, MacConnell P, Simsir A, Valea F, French D. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995;55:267-75.
33. Davidson B, Goldberg I, Kopolovic J et al. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix a clinicopathologic study using inmunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999;72:380-6.
34. Davidson B, Goldberg I, Kopolovic J et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma a clinicopathologic study using inmunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999;73:372-82.
35. Garzetti G, Ciavattini A, Lucarini G, Goteri G, Romanini C, Biagini G. The 72-kDa metalloproteinase immunostaining in cervical carcinoma: relationship with lymph nodal involvement. Gynecol Oncol 1996;60:271-6.
36. Garzetti G, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Biagini G. Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol Oncol 1996;61:197-203.
37. Talvensaari-Mattila A, Apaja-Sarkkinen M, Höyhtyä M, Westerlund A, Puistola U, Turpeenniemi-Hujanen T. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol 1999;72:306-11.
38. Daneri-Narro A, Del Toro-Arreola S, Bravo-Cuellar A, Cabrera N, Orbach-Arbouys S, Perez-Montfort R. Proteolytic activity in extracts of invasive cervical carcinoma and precursor lesions. Biomed Pharmacother 1995;49:304-10.
39. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
40. Kishi J, Tanaka R, Koiwai O et al. Gelatinases and metalloproteinase inhibitor secreted by murine colonic carcinoma cells with differing metastatic potential. Cell Biol Int 1994;18:165-70.
41. Garzetti G, Ciavattini A, Lucarini G et al. The role of human papillomavirus in cervical carcinoma and risk of lymph node metastasis. Association with 72-kilodalton metalloproteinase immunostaining. Cancer 1998;82:886-92.
42. Matrisian L. Matrix metalloproteinase gene expression. Ann NY Acad Sci 1994;732:42-9.
43. Sternlicht MD, Lochter A, Sympson CJ et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-46.
44. Ramos-DeSimone N, Han-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999;274:13066-76.
45. Sternlicht MD, Bissell MJ, Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 2000;19:1102-13.
46. Tsukifuji R, Tagawa K, Hatamochi A, Shinkai H. Expression of matrix metalloproteinase-1-2 and -3 in squamous cell carcinoma and actinic keratosis. Br J Cancer 1999;80:1087-91.
47. Randal ME, Constable WC, Halm SS. Results of the radiotherapeutic management of carcinoma of the cervix with emphasis on the influence of histologic classification. Cancer 1999;62:1980-8.
48. Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 1990;82:1890-8.
49. Koshikawa N, Yasumitsu H, Umeda M, Miyazaki K. Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res 1992;52:5046-53.
50. Vartio T, Baumann M. Human gelatinase/type IV procollagenase is a regular plasma component. FEBS Lett 1989;255:285-7.
51. Yuki K, Uozumi T, Kodama Y, Kurisu K, Takashi M. In vitro chemosensitivity test of human brain tumors using three-dimensional organ culture with collagen gel matrix. J Neurooncol 1994;21:225-32.
52. Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1992;84:394-8.
53. Gilles C, Polette M, Piette J, Birembaut P, Foidart J-M. Epithelial-mesenchymal transition in HPV-33-transfixed cervical keratinocytes is associated with increased invasiveness and expression of gelatinase A. Int J Cancer 1994;59:661-6.
54. Kolkhorst V, Stürzebecher J, Wiederanders B. Inhibition of tumour cell invasion by protease inhibitors: correlation with the protease profile. J Cancer Res Clin Oncol 1998;24:598-606.